To see the other types of publications on this topic, follow the link: Ppam.
Journal articles on the topic 'Ppam'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Ppam.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Orzuna-Orzuna, José Felipe, Alejandro Lara-Bueno, Adrián Gloria-Trujillo, Germán David Mendoza-Martínez, Luis Alberto Miranda-Romero, and Pedro Abel Hernández-García. "Growth Performance, Dietary Energetics, Blood Metabolites, Carcass Traits, Meat Quality, and Gene Expression of Lambs Supplemented with a Polyherbal Phytogenic Additive." Veterinary Sciences 11, no. 11 (October 25, 2024): 520. http://dx.doi.org/10.3390/vetsci11110520.
Full textAbstract:
This study aimed to evaluate the effects of supplementation with a polyherbal phytogenic additive (PPA) on the productive performance, dietary energetics, blood metabolites, carcass traits, meat quality, and gene expression of finishing lambs. Thirty-six male Pelibuey lambs (23.61 ± 0.57 kg body weight (BW)) were housed in individual pens and assigned to four treatments (n = 9) with different doses of PPA: 0 (CON), 2.5 (PPAL), 5 (PPAM), and 7.5 (PPAH) g of PPA/kg of DM for 56 days. Average daily gain, dry matter intake, and observed dietary net energy for maintenance and weight gain increased linearly (p < 0.05) in lambs supplemented with PPAH. A linear reduction (p = 0.02) in FCR was detected in lambs fed PPAM and PPAH. The PPAH supplementation linearly increased (p < 0.001) Longissimus dorsi muscle area, but other carcass traits were not affected (p > 0.05) by PPA doses. The physicochemical characteristics of the meat and the hematological parameters of the lambs were not affected (p > 0.05) by the PPA doses. The glucose, uric acid, creatinine, and bilirubin serum concentrations decreased linearly (p < 0.05) in lambs supplemented with PPAM and PPAH. Gene ontology analyses showed that nine biological processes were modified (p < 0.05), including DNA replication, drug metabolism–cytochrome P450, oxidative phosphorylation, and chemical carcinogenesis–reactive oxygen species. In conclusion, high doses (7.5 g/kg DM) of PPA can improve growth performance and dietary energy utilization efficiency in finishing lambs. Likewise, gene expression analysis indicates that supplementation with high doses of PPA could improve energy production and antioxidant status in finishing lambs.
2
Kholifah, Siti, Resti Utami, Alfia Indah Juwita, Dayinta Wintang Rukmi, and Aliyah Ratnaning Palupi. "Edukasi Pedoman Paket Pelayanan Awal Minimum (PPAM) Kesehatan Reproduksi Fase Pra Krisis Kesehatan Pada Perempuan Pengrajin Genteng." Jurnal Pengabdian Masyarakat IPTEKS 9, no. 1 (June 26, 2023): 90–95. http://dx.doi.org/10.32528/jpmi.v9i1.653.
Full textAbstract:
Edukasi tentang PPAM kesehatan reproduksi pada fase pra krisis merupakan penyiapan perempuan jika saat terjadi bencana perempuan dapat terpenuhi kebutuhan akan Kesehatan reproduksi meskipun fasilitas pelayanan kesehatan tidak berfungsi atau akses terhadap pelayanan kesehatan reproduksi sulit terjangkau oleh perempuan yang terdampak. Pemberian edukasi pada perempuan terutama tentang PPAM merupakan salah satu upaya untuk meningkatkan pengetahuan guna mengurangi risiko kesakitan dan kematian kelompok rentan kesehatan reproduksi jika terjadi bencana. Mengingat sasaran PPAM adalah masyarakat yang merupakan kelompok rentan kesehatan reproduksi yaitu bayi baru lahir, ibu hamil, ibu bersalin, ibu pascapersalinan, ibu menyusui, anak perempuan, remaja dan wanita usia subur. Adapun metode yang telah dilakukan adalah edukasi penerapan PPAM, pemberdayaan mitra, dan keberlanjutan program, antara lain: 1) tahap persiapan; 2) tahap edukasi PPAM; 3) tahap evaluasi pelaksanaan edukasi PPAM. Hasil edukasi PPAM adalah adanya peningkatan yang signifikan terkait pengetahuan perempuan pengrajin genteng tentang PPAM. Hendaknya peran serta dinas terkait, BPBD, perangkat desa dan tokoh masyarakat dioptimalkan untuk meningkatkan kesadaran masyarakat akan siaga bencana.
3
Himarosa, Rela Adi, Sudarisman Sudarisman, Ammaru Bisandyaloka, and Fajar Sofyantoro. "Pengembangan Unit Usaha Tempe melalui Aplikasi Mesin Giling Kedelai Teknologi Screw." Jurnal Pengabdian Pada Masyarakat 7, no. 2 (May 31, 2022): 298–307. http://dx.doi.org/10.30653/002.202272.72.
Full textAbstract:
DEVELOPMENT OF TEMPE PRODUCTION UNIT THROUGH THE APPLICATION OF SOYBEAN SCREW-TYPE MILLING MACHINES. Pondok Pesantren Asy-Syifa’ Muhammadiyah (PPAM), located in Yogyakarta, aims to become an independent and benevolent institution for the community. To realize its noble missions, PPAM initiated the Tempe Production Unit (TPU) as an alternative source of financial incomes and to provide nutritional foods for its students. The TPU at PPAM was established through the application of the screw-type milling machine, which is more efficient, time-saving and hygienic compared to traditional milling methods. The community service program at PPAM was initiated by involving the administrators in an intensive discussion to analyze the required resources and future prospects of TPU. The manufacturing process of milling machine was carried out at Universitas Muhammadiyah Yogyakarta, followed by training of the PPAM members in operating the milling machine. The PPAM members enthusiastically participated and provided valuable inputs for the machine adjustments. Before officially handing the milling machine to PPAM, the machine has been adjusted in accordance with the PPAM members suggestions. Evaluation and monitoring were carried out during the initial production stages, which has been successfully processing 4 kg of soybeans into 20 packs of tempeh per day.
4
Varricchione, Giovanni, Natasha Alechina, Mehdi Dastani, Giuseppe De Giacomo, Brian Logan, and Giuseppe Perelli. "Pure-Past Action Masking." Proceedings of the AAAI Conference on Artificial Intelligence 38, no. 19 (March 24, 2024): 21646–55. http://dx.doi.org/10.1609/aaai.v38i19.30163.
Full textAbstract:
We present Pure-Past Action Masking (PPAM), a lightweight approach to action masking for safe reinforcement learning. In PPAM, actions are disallowed (“masked”) according to specifications expressed in Pure-Past Linear Temporal Logic (PPLTL). PPAM can enforce non-Markovian constraints, i.e., constraints based on the history of the system, rather than just the current state of the (possibly hidden) MDP. The features used in the safety constraint need not be the same as those used by the learning agent, allowing a clear separation of concerns between the safety constraints and reward specifications of the (learning) agent. We prove formally that an agent trained with PPAM can learn any optimal policy that satisfies the safety constraints, and that they are as expressive as shields, another approach to enforce non-Markovian constraints in RL. Finally, we provide empirical results showing how PPAM can guarantee constraint satisfaction in practice.
5
Cruz-Torres, Karla Catalina, Samuel Estrada-Soto, Luis Arias-Durán, Gabriel Navarrete-Vázquez, Julio César Almanza-Pérez, Beatriz Mora-Ramiro, Irene Perea-Arango, et al. "LC-MS Fingerprinting Development for Standardized Precipitate from Agastache mexicana, Which Induces Antihypertensive Effect through NO Production and Calcium Channel Blockade." Pharmaceutics 15, no. 9 (September 19, 2023): 2346. http://dx.doi.org/10.3390/pharmaceutics15092346.
Full textAbstract:
The aim of this work was to evaluate the vasorelaxant and antihypertensive effects of a standardized precipitate of the hydroalcoholic extract from Agastache mexicana (PPAm), comprising ursolic acid, oleanolic acid, acacetin, luteolin and tilianin, among others. In the ex vivo experiments, preincubation with L-NAME (nonspecific inhibitor of nitric oxide synthases) reduced the relaxation induced by PPAm; nevertheless, preincubation with indomethacin (nonspecific inhibitor of cyclooxygenases) did not generate any change in the vasorelaxation, and an opposed effect was observed to the contraction generated by CaCl2 addition. Oral administration of 100 mg/kg of PPAm induced a significant acute decrease in diastolic (DBP) and systolic (SBP) blood pressure in spontaneously hypertensive rats, without changes in heart rate. Additionally, PPAm showed a sustained antihypertensive subacute effect on both DBP and SBP for 10 days compared to the control group. On the other hand, human umbilical vein cells treated with 10 µg/mL of PPAm showed a significant reduction (p < 0.05) in intracellular adhesion molecule-1, compared to the control, but not on vascular cell adhesion molecule-1. In conclusion, PPAm induces a significant antihypertensive effect in acute- and subacute-period treatments, due to its direct vasorelaxant action on rat aortic rings through NO production and Ca2+ channel blockade.
6
David S, Alex, Ravikumar S, and Antony Kumar K. "Lossless MRI compression utilizing prediction by partial approximate matching." International Journal of Engineering & Technology 7, no. 1.7 (February 5, 2018): 115. http://dx.doi.org/10.14419/ijet.v7i1.7.9595.
Full textAbstract:
MRI is a medicinal imaging system utilized as a part of radiology to picture the inner structure of the human body for the analysis of various sorts of wounds and conditions in a non– obtrusive way. A standout amongst the most difficult issues in therapeutic imaging is pressure of the information to be sent over fitting transmission lines with no misfortune in data. Setting based displaying gives high spatial determination and differentiation affectability necessities for the analytic reason. Since, it is attractive to have exact lossless pressure of MRI picture, execute the Prediction by Partial Approximate Matching (PPAM). PPAM models the likelihood of the encoding image in view of its past settings, whereby setting events are considered in an inexact settings proficiently, store the settings that have been beforehand seen in a tree structure, called the PPAM setting tree.
7
Hadley, AW, AD McDowell, and BD Whitlock. "Calibration of Physiotherapy PPAM aids." Physiotherapy 77, no. 3 (March 1991): 179–80. http://dx.doi.org/10.1016/s0031-9406(10)61697-5.
Full text
8
García Rodríguez, José Félix, Carlos Lezama León, Aída Beatriz Armenta Ramírez, and Luis Arturo Méndez Olán. "IMPACTO DEL PROGRAMA PENSIÓN PARA ADULTOS MAYORES (PPAM) EN TABASCO, MÉXICO. PERÍODO 2013-2015." Hitos de Ciencias Económico Administrativas 23, no. 65 (May 4, 2017): 38–51. http://dx.doi.org/10.19136/hitos.a0n65.1820.
Full textAbstract:
Objetivo: Analizar el impacto en Tabasco del Programa Pensión para Adultos Mayores (PPAM) entre sus beneficiarios en pobreza extrema, durante el período 2013-2015, buscando confirmar la hipótesis de que dichos beneficiarios mejoraron sus condiciones de bienestar debido a su incorporación al PPAM.
Material y método: Se desarrolló una investigación cuantitativa de tipo descriptivo no experimental. La población objeto de estudio fueron los hogares con adultos mayores en pobreza extrema del municipio de Centro, determinándose un universo poblacional de 4,122 beneficiarios y un marco muestral de 314 hogares identificados en pobreza extrema, obteniéndose por muestreo aleatorio simple una muestra representativa de 173 hogares.
Resultados: Los resultados de la investigación permiten afirmar que los hogares con adultos mayores de 65 años en pobreza extrema mejoraron en general sus condiciones socioeconómicas.
Conclusiones: Los adultos mayores del municipio de Centro, Tabasco, que en el año 2013 se encontraban en condiciones de pobreza extrema, al año 2015 observaron una importante disminución en sus carencias básicas, debido a su incorporación al PPAM.
9
Scott, H., M. E. Condie, S. P. Treweek, and S. Sockalingam. "An evaluation of the Amputee Mobility Aid (AMA) early walking aid." Prosthetics and Orthotics International 24, no. 1 (April 2000): 39–46. http://dx.doi.org/10.1080/03093640008726520.
Full textAbstract:
The most popular early walking aid (EWA) in the United Kingdom (UK) is the Pneumatic PostAmputation Mobility aid or PPAM aid. A disadvantage of this device is that it does not allow a transtibial amputee to flex or extend the knee during walking. The Amputee Mobility Aid (AMA) was developed to allow knee movement, enabling transtibial amputees to practise a more natural gait. The benefits of using EWAs include early walking, reduction in postoperative oedema and improvement in patient morale. This pilot study investigated the pneumatic bag/stump interface pressures of the PPAM aid and the AMA. In addition, the range of motion of the knee on the amputated side and the mechanical knee of the AMA were compared. The AMA was found to have higher interface pressures than the PPAM aid during standing and similar pressures during supported walking. Subjects using the AMA did flex and extend their knee during walking but through a reduced range of motion. There were no significant differences between the angular movements of the AMA's mechanical knee and the patient's knee within it.
10
Kholifah, Siti, Resti Utami, Elfira Damayanti, and Della Nur Muthmainnah Qalbi. "EDUKASI VIRTUAL SEBAGAI UPAYA PENINGKATAN PENGETAHUAN DAN SIKAP REMAJA TENTANG PELAKSANAAN PAKET PELAYANAN AWAL MINIMUM (PPAM) KESEHATAN REPRODUKSI REMAJA PADA SITUASI KESIAPSIAGAAN BENCANA." PROFESSIONAL HEALTH JOURNAL 5, no. 1sp (October 10, 2023): 124–29. http://dx.doi.org/10.54832/phj.v5i1sp.442.
Full textAbstract:
Remaja merupakan menjadi salah satu kelompok rentan pada situasi bencana, tetapi bisa juga menjadi mediator menyampaikan informasi terkait Kesehatan reproduksi remaja dalam kesiapsiagaan bencana maupun saat terjadi bencana, sehingga remaja harus memiliki pengetahuan dan sikap kesiapsiagaan bencana yang adekuat. Pengetahuan dan perilaku kesiapsiagaan pada remaja dapat ditingkatkan melalui edukasi dengan menggunakan edukasi virtual terkait pelaksanaan Paket Pelayanan Awal Minimum (PPAM) untuk kesehatan reproduksi remaja pada situasi kesiapsiagaan bencana. Metode penelitian yang digunakan adalah Quasy Eksperimental dengan rancangan Pretest and Post test. Penelitian ini dilakukan pada bulan Mei 2023 di Prodi Ilmu Keperawatan Universitas Muhammadiyah Jember dengan melibatkan 62 responden yang diperoleh secara purposive sampling. Kriteria inklusi adalah mahasiswi Prodi Ilmu Keperawatan yang berada di tahun pertama kuliah dan belum pernah mendapatkan edukasi tentang PPAM. Data penelitian diperoleh melalui kuesioner elektronik. Uji statistik menggunakan Paired Sampel T-Test. Hasil perhitungan uji paired t-test didapatkan nilai p value (Asymp.Sig 2 tailed) sebesar 0.0001 dimana kurang dari 0.05 sehingga keputusan hipotesis H1 diterima yang berarti terdapat pengaruh edukasi virtual terhadap pengetahuan dan sikap remaja tentang PPAM kesehatan reproduksi remaja pada situasi kesiapsiagaan bencana. Hendaknya edukasi siaga bencana terhadap remaja dapat dilakukan secara berkala dengan melibatkan lintas sektoral.
11
Himarosa, Rela Adi, Krisdiyanto Krisdiyanto, Primadian Adhi Wardana, Nur Rachman Maulana, and Fajar Sofyantoro. "Pemberdayaan UMKM melalui Inovasi Marketing berbasis Teknologi Informasi." PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat 7, no. 6 (November 28, 2022): 774–81. http://dx.doi.org/10.33084/pengabdianmu.v7i6.4099.
Full textAbstract:
Pondok Pesantren Asy-Syifa' Muhammadiyah (PPAM) in Yogyakarta established several Micro, Small and Medium Enterprises (MSMEs) including production units of tempeh, mineral water, coffee, and donut. The main obstacle experienced by the MSMEs is the traditional marketing system which limits the sales of products. The current program aimed to assist the adoption of information technology, especially in marketing techniques using social media and e-commerce. The activities included discussions with MSMEs owners, socialization of marketing techniques, creating social media accounts, making of product catalogs, and evaluation. In general, all the activities could be carried out as targeted. After participating in this program, the MSME owners at PPAM are able to use social media and e-commerce to increase product marketing and sales.
12
Najarian, Dean, Panna Sanga, Steven Wang, Pilar Lim, Arun Singh, Mary Jane Robertson, Kristin Cohen, et al. "A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia." International Journal of Neuropsychopharmacology 25, no. 3 (November 13, 2021): 238–51. http://dx.doi.org/10.1093/ijnp/pyab071.
Full textAbstract:
Abstract Background This double-blind (DB), randomized, parallel-group study was designed to evaluate efficacy and safety of paliperidone palmitate 6-month (PP6M) formulation relative to paliperidone palmitate 3-month (PP3M) formulation in patients with schizophrenia. Methods Following screening, patients entered an open-label (OL) maintenance phase and received 1 injection cycle of paliperidone palmitate 1-month (PP1M; 100 or 150 mg eq.) or PP3M (350 or 525 mg eq.). Clinically stable patients were randomized (2:1) to receive PP6M (700 or 1000 mg eq., gluteal injections) or PP3M (350 or 525 mg eq.) in a 12-month DB phase; 2 doses of PP6M (corresponding to doses of PP1M and PP3M) were chosen. Results Overall, 1036 patients were screened, 838 entered the OL phase, and 702 (mean age: 40.8 years) were randomized (PP6M: 478; PP3M: 224); 618 (88.0%) patients completed the DB phase (PP6M: 416 [87.0%]; PP3M: 202 [90.2%]). Relapse rates were PP6M, 7.5% (n = 36) and PP3M, 4.9% (n = 11). The Kaplan-Meier estimate of the difference (95% CI) between treatment groups (PP6M − PP3M) in the percentages of patients who remained relapse free was −2.9% (−6.8%, 1.1%), thus meeting noninferiority criteria (95% CI lower bound is larger than the pre-specified noninferiority margin of −10%). Secondary efficacy endpoints corroborated the primary analysis. Incidences of treatment-emergent adverse events were similar between PP6M (62.1%) and PP3M (58.5%). No new safety concerns emerged. Conclusions The efficacy of a twice-yearly dosing regimen of PP6M was noninferior to that of PP3M in preventing relapse in patients with schizophrenia adequately treated with PP1M or PP3M. Trial Registration Clinical Trials.gov identifier: NCT03345342
13
Alcivar-Cevallos, Roberth, Wilson Alexander Ávila-Briones, and Max Chacón-Pacheco. "Detección de autorregulación cerebral deteriorada basada en el plano complejidad - entropía." CIENCIAMATRIA 6, no. 1 (November 28, 2020): 827–59. http://dx.doi.org/10.35381/cm.v6i1.417.
Full textAbstract:
Se propone una metodología para clasificar señales fisiológicas que representan la autorregulación cerebral (AC), utilizando cuantificadores como complejidad estadística y entropía. Los cuales se obtienen a partir de datos de velocidad de flujo sanguíneo cerebral (VFSC) y presión arterial media (PAM) disponibles en dos bases de datos. Los resultados para el análisis de señales en el plano C-H, donde se grafican los valores de complejidad y entropía de las señales de VFSC, muestran valores de AUC=90,18 %, mientras que en el caso de ∆ C-H, que es obtenido graficando los cambios en la entropía (∆H = H[PVFSC]−H[PPAM]) versus los cambios en complejidad (∆C = C[PVFSC]−C[PPAM]) con lo que se obtienen valores de AUC=94,26 % demostrando la capacidad que tiene el método en términos de clasificación.
14
David S, Alex, Almas Begum, and Ravikumar S. "Content clustering for MRI Image compression using PPAM." International Journal of Engineering & Technology 7, no. 1.7 (February 5, 2018): 126. http://dx.doi.org/10.14419/ijet.v7i1.7.10631.
Full textAbstract:
Image compression helps to save the utilization of memory, data while transferring the images between nodes. Compression is one of the key technique in medical image. Both lossy and lossless compressions where used based on the application. In case of medical imaging each and every components of pixel is very important hence its nature to chose lossless compression medical images. MRI images are compressed after processing. Here in this paper we have used PPMA method to compress the MRI image. For retrieval of the compressed image content clustering method used.
15
Ham, Rosalind, Paul Richardson, and Angela Sweet. "A New Look at the Vessa PPAM Aid." Physiotherapy 75, no. 8 (August 1989): 493–94. http://dx.doi.org/10.1016/s0031-9406(10)62660-0.
Full text
16
RUIZ, Julia da Silva Gutierrez, and Leandro Pereira MORAIS. "O ESPAÇO DAS POLÍTICAS PÚBLICAS DE ECONOMIA SOLIDÁRIA NA PREVISÃO ORÇAMENTÁRIA DO MUNICÍPIO DE ARARAQUARA-SP." ORG & DEMO 24 (November 9, 2023): e023015. http://dx.doi.org/10.36311/1519-0110.2023.v24.e023015.
Full textAbstract:
O presente trabalho tem como objetivo observar o histórico de políticas públicas para Economia Solidária (ESOL) presentes no município de Araraquara-SP (uma vez que este é considerado um exemplo de “boas práticas” de políticas públicas de ESOL), observando também, a partir dos Plano Plurianuais Municipais (PPAm), qual o espaço da temática de temas transversais à ESOL dentro da previsão orçamentária municipal, para fazer uma reflexão sobre a quantidade/intensidade dessas políticas públicas e quanto elas ocupam dentro da previsão orçamentária. A metodologia utilizada neste trabalho foi de revisão bibliográfica narrativa e integrativa e, então, uma descrição dos programas e valores presentes nos PPAm de Araraquara referentes às políticas de ESOL e temas transversais. Araraquara-SP é um município que conta com uma grande proposta de políticas públicas subnacionais em ESOL, porém o orçamento para estas políticas ainda é bem limitado: além de ser oscilante (o que demonstra ser uma agenda de governo e não de Estado – e estável), o valor previsto para as políticas de ESOL é muito pequeno em relação ao valor municipal que, assim como as políticas transversais, possui um valor crescente com os passar dos quadriênios.
17
Richarz, Ute, John Han, Ya-Mei Bai, Eric Yu-Hai Chen, Young Chul Chung, Venu Gopal Jhanwar, Sung-Wan Kim, Ahmad Hatim Sulaiman, Karl Knight, and Srihari Gopal. "Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study." Medicine 102, no. 34 (August 25, 2023): e34623. http://dx.doi.org/10.1097/md.0000000000034623.
Full textAbstract:
Background: Evaluate efficacy and safety of paliperidone palmitate 6-monthly (PP6M) for patients with schizophrenia in the Asian subgroup of a global, multicenter, noninferiority phase-3 study (NCT03345342). Methods: Patients received paliperidone palmitate 1-monthly (PP1M, 100/150 mg eq.) or paliperidone palmitate 3-monthly (PP3M, 350/525 mg eq.) during the maintenance phase and entered a 12-month double-blind (DB) phase, wherein they were randomized (2:1) to PP6M (700/1000 mg. eq.) or PP3M (350/525 mg eq.). Subgroup analysis was performed for 90 (12.7%) patients from Asia region (India, Taiwan, Malaysia, Hong Kong, and Korea). Primary endpoint was time-to-relapse during DB phase (Kaplan–Meier estimates). Secondary endpoints were changes from baseline in Positive and Negative Syndrome Scale, Clinical Global Impression-Severity scale, Personal and Social Performance (PSP) scale score. Results: In Asian subgroup, 91.9% (82/90) of patients completed DB phase (PP6M: 54/62 [87%]; PP3M: 28/28 [100%]). Median time-to-relapse was “not-estimable” due to low relapse rates in both groups. Estimated difference (95% confidence interval [CI]) between relapse-free patients in PP6M and PP3M groups of Asian subgroup was −0.1% [−8.5%, 8.4%] (global study population: −2.9% [−6.8%, 1.1%]). Mean change from baseline in secondary efficacy parameters was comparable between both groups, similar to the global study population. The incidence of extrapyramidal symptoms was higher in the Asian subgroup than in the global study population. Conclusion: Consistent with the global study population, PP6M was noninferior to PP3M in preventing relapse in patients with schizophrenia from the Asia region. Findings suggest the possibility of switching from PP1M/PP3M to twice-yearly PP6M without loss of efficacy and with no unexpected safety concerns.
18
Velázquez-Cruz, Lucero Abigail, German David Mendoza-Martínez, Pedro Abel Hernández-García, Enrique Espinosa-Ayala, Cesar Díaz-Galván, Gabriela Vázquez-Silva, José Felipe Orzuna-Orzuna, Pablo Benjamín Razo-Ortíz, and María Eugenia de la Torre-Hernández. "Growth Performance, Health Parameters, and Blood Metabolites of Dairy Calves Supplemented with a Polyherbal Phytogenic Additive." Animals 15, no. 4 (February 17, 2025): 576. https://doi.org/10.3390/ani15040576.
Full textAbstract:
This study aimed to evaluate the effects of dietary supplementation with increasing levels of a polyherbal phytogenic additive (PPA) on growth performance, health parameters, and blood metabolites of dairy calves. Forty female Holstein calves (43.35 ± 2.41 kg body weight and 25.1 ± 2.2 d of age) were housed in individual pens and randomly assigned to four treatments (n = 10) with increasing levels of PPA: 0 (CON), 2 (PPA2), 3 (PPA3), and 4 (PPA4) g PPA/d for 67 d. Compared to the CON treatment, supplementation with the PPA2 treatment increased (quadratic effect p = 0.02) the average daily gain and final body weight of the dairy calves. Also, a higher starter intake (SI), and intake of milk + milk replacer was observed (linear and quadratic effect p = 0.0001) in response to supplementation with the PPA2, PPA3, and PPA4 treatments. The evaluated treatments did not affect (p > 0.05) the feed conversion ratio, or the number of cases of diarrhea, pneumonia, and otitis. The evaluated treatments did not affect (p > 0.05) most of the hematological and biochemical blood parameters. However, compared to the CON treatment, supplementation with the PPA2 treatment increased (quadratic effect p < 0.05) the blood concentration of the segmented neutrophils and plasma protein. Likewise, the serum glucose concentration decreased (linear effect p < 0.05) with supplementation of the PPA2, PPA3, and PPA4 treatments. Compared with the CON treatment, the PPA4 supplementation decreased the serum urea concentration (linear effect p = 0.04). In conclusion, supplementation with 2 g/d of PPA can be used as a natural alternative to improve the growth rate and stimulate starter and milk + milk replacer intake in dairy calves without adverse effects on health parameters or blood metabolites.
19
Woźniakowski, Grzegorz, Natalia Mazur-Panasiuk, Marek Walczak, Małgorzata Juszkiewicz, Maciej Frant, and Krzysztof Niemczuk. "Attempts at the development of a recombinant African swine fever virus strain with abrogated EP402R, 9GL, and A238L gene structure using the CRISPR/Cas9 system." Journal of Veterinary Research 64, no. 2 (June 3, 2020): 197–205. http://dx.doi.org/10.2478/jvetres-2020-0039.
Full textAbstract:
AbstractIntroductionAfrican swine fever (ASF) is a pressing economic problem in a number of Eastern European countries. It has also depleted the Chinese sow population by 50%. Managing the disease relies on culling infected pigs or hunting wild boars as sanitary zone creation. The constraints on the development of an efficient vaccine are mainly the virus’ mechanisms of host immune response evasion. The study aimed to adapt a field ASFV strain to established cell lines and to construct recombinant African swine fever virus (ASFV) strain.Material and MethodsThe host immune response modulation genes A238L, EP402R, and 9GL were deleted using the clustered regularly interspaced short palindromic repeats/caspase 9 (CRISPR/Cas9) mutagenesis system. A representative virus isolate (Pol18/28298/Out111) from Poland was isolated in porcine primary pulmonary alveolar macrophage (PPAM) cells. Adaptation of the virus to a few established cell lines was attempted. The plasmids encoding CRISPR/Cas9 genes along with gRNA complementary to the target sequences were designed, synthesised, and transfected into ASFV-infected PPAM cells.ResultsThe reconstituted virus showed similar kinetics of replication in comparison to the parent virus isolate.ConclusionTaking into account the usefulness of the developed CRISPR/Cas9 system it has been shown that modification of the A238L, EP402R, and 9GL genes might occur with low frequency, resulting in difficulties in separation of various virus populations.
20
Wyrzykowski, Roman, and Marek Tudruj. "10th international conference on Parallel Processing and Applied Mathematics, PPAM 2013." Concurrency and Computation: Practice and Experience 27, no. 4 (November 7, 2014): 882–84. http://dx.doi.org/10.1002/cpe.3430.
Full text
21
Oliveira, Carmem Sara Pinheiro de, Aleson da Silva Fonseca, and Magnólia Fernandes Florêncio de Araújo. "Water quality and cyanobacterial blooms in the Piancó-Piranhas-Açu Watershed, Semi-arid Region of Northeastern Brazil: relationships with education toward sustainability." Revista Ibero-Americana de Ciências Ambientais 13, no. 3 (July 2, 2022): 339–55. http://dx.doi.org/10.6008/cbpc2179-6858.2022.003.0027.
Full textAbstract:
Greater emphasis has been attached to aquatic ecosystems in recent decades, as these are associated with indicators determinant of sustainability indices. The environmental impacts of these ecosystems with potential risk to human health in the semi-arid region of the state of Rio Grande do Norte have been frequently observed. This study aimed at evaluating the cyanobacteria density, and the indices that indicate the Piancó-Piranhas-Açu Watershed quality. It also targeted to identify the factors that impact most the blooming of these aquatic organisms. The sampling design consisted of 12 collections in different seasonal periods from 2009 to 2016, carried out by the Água Azul Program on 6 points along the basin. Environmental variables were used to analyze the Water Quality Index (WQI), Trophic State Index (TSI), and Cyanobacteria Density (CD). The mean WQI indicated ‘Regular’ water status for points PPA3 and PPA4, while PPA1, PPA2, PPA5 and PPA6 resulted in ‘Good’. As for the TSI, the levels indicate average degree of eutrophication (mesotrophy) on three sampling points, high degree of eutrophication (eutrophy) on two points, and low degree of eutrophication (oligotrophy) on one point. In this sense, human activities - especially diffuse polluting sources - around the spring seemed to worsen these scenarios. The density of potentially toxic cyanobacteria was high, exceeding CONAMA Resolution 357/2005 that recommends a maximum value of 50,000 cells/mL, and the Ministry of Health Ordinance 2914/2011 that recommends a threshold of 20,000 cells/mL. Regarding the general correlation between CD and seasonality we found significant influence (p < 0.05), with greater proliferation of these organisms directly related to periods of drought. We concluded that although the WQI indicated that dams’ waters are suitable for multiple uses, the TSI had limitations, considering the excessive primary productions associated with the presence of cyanobacteria and, thus, the potential occurrence of cyanotoxins ensuing from pollutant loads. The study led us to conclude that the adoption of education practices toward sustainability would help environmental preservation and local social development. It would also enable the establishment of effective priority public policies on mitigation of water pollution.
22
Mesones, J., A. Miller, N. Bautista, J. Dieguez, I. Calero, and A. Griñant. "Descriptive study of 100 patients with a diagnosis of psychosis treated with Paliperidone Palmitate 6-Month Long-Acting Injectable." European Psychiatry 67, S1 (April 2024): S387. http://dx.doi.org/10.1192/j.eurpsy.2024.796.
Full textAbstract:
IntroductionPsychotic disorders are serious mental illnesses that require long-term antipsychotic treatment that provides sufficient efficacy, safety and therapeutic adherence. The latter is an essential factor that must be emphasized in clinical practice in order to avoid relapses. On this occasion, we have the need to know the long-term impact on our clinical practice and on the evolution of patients after the change in formulation of paliperidone palmitate 1 (PP1M) and 3 Month long-acting injectable antipsychotic (PP3M) to paliperidone palmitate 6 Month (PP6M).ObjectivesThe present study describes a sample of patients with severe mental disorders (n= 100) treated with six-monthly paliperidone palmitate (PP6M) studying the diagnoses, socio-demographic characteristics, number of relapses, tolerability and treatment adherence of patients.MethodsProspective descriptive study with a sample selected by non-probabilistic consecutive sampling, retrospective type, in a time interval of 15 month (n= 100 outpatients). The patients selected were all those who received 6 monthly paliperidone palmitate treatment from May 2022 to September 2023. A descriptive analysis was performed. Mean and standard deviation were calculated for quantitative variables and N and percentage for categorical variables.ResultsProspective study with consecutive sampling of 100 outpatients (62% men, 38% women; mean age 48 years) diagnosed with psychosis (76 % Schizophrenia, 21 % Unspecified psychosis, 3 % Delusional disorder) those who are administered PP6M long-acting injectable antipsychotic previously treated with PP1M (35%) and PP3M (65%).After 15 months of the study, 4 patients (4%) have suffered a relapse, one of them (1%) requiring hospitalization. 5 patients (4%) declined to continue PP6M and have returned to their previous injectable. 1 patient (1%) has died of unknown causes outside the treatment. 90 patients continue treatment with PP6M (90% retention rate). 54 patients maintain antipsychotic monotherapy (54%). No additional adverse effects were reported after switching to PP6M. The subjective perception of satisfaction after the switch to PP6M by patients and caregivers was very high.ConclusionsThe present real clinical practice study shows that PP6M could be an effective and well tolerated treatment in patients with severe mental disorder, for patients diagnosed with psychosis, with a high rate of relapse prevention and high rates of compliance. Changing treatment from PP1M or PP3M to PP6M could help patients with severe mental disorder to normalize their lives and functionality.Disclosure of InterestNone Declared
23
Tang, Gang, Hongren Zhao, Christophe Claramunt, Weidong Zhu, Shiming Wang, Yide Wang, and Yuehua Ding. "PPA-Net: Pyramid Pooling Attention Network for Multi-Scale Ship Detection in SAR Images." Remote Sensing 15, no. 11 (May 31, 2023): 2855. http://dx.doi.org/10.3390/rs15112855.
Full textAbstract:
In light of recent advances in deep learning and Synthetic Aperture Radar (SAR) technology, there has been a growing adoption of ship detection models that are based on deep learning methodologies. However, the efficiency of SAR ship detection models is significantly impacted by complex backgrounds, noise, and multi-scale ships (the number of pixels occupied by ships in SAR images varies significantly). To address the aforementioned issues, this research proposes a Pyramid Pooling Attention Network (PPA-Net) for SAR multi-scale ship detection. Firstly, a Pyramid Pooled Attention Module (PPAM) is designed to alleviate the influence of background noise on ship detection while its parallel component favors the processing of multiple ship sizes. Different from the previous attention module, the PPAM module can better suppress the background noise in SAR images because it considers the saliency of ships in SAR images. Secondly, an Adaptive Feature Balancing Module (AFBM) is developed, which can automatically balance the conflict between ship semantic information and location information. Finally, the detection capabilities of the ship detection model for multi-scale ships are further improved by introducing the Atrous Spatial Pyramid Pooling (ASPP) module. This innovative module enhances the detection model’s ability to detect ships of varying scales by extracting features from multiple scales using atrous convolutions and spatial pyramid pooling. PPA-Net achieved detection accuracies of 95.19% and 89.27% on the High-Resolution SAR Images Dataset (HRSID) and the SAR Ship Detection Dataset (SSDD), respectively. The experimental results demonstrate that PPA-Net outperforms other ship detection models.
24
Francis, Jennifer, Reanee Lee, Intan Sazrina Saimy, Nor Ashikin Mohamed Yusof, Fadillah Ismail, and Abdul Muhaimin Zamri. "Comparative Study of Malaysian Affordable Housing Policy Initiatives." Journal of Science, Technology and Innovation Policy 9, no. 2 (January 5, 2024): 1–10. http://dx.doi.org/10.11113/jostip.v9n2.137.
Full textAbstract:
The Malaysian government has implemented and coordinated affordable housing development initiatives to many targeted groups with the aim to spearhead liveable affordable housing and establish an effective regulatory on affordable housing. In order to focus on the direction as well as formulating guidelines for the development of affordable houses, the National Affordable Housing Policy (NAHP) had taken into account the problems and issues faced by the public especially on the inability to own a house at the market rates. Through this policy, several government initiatives were implemented, including Perumahan Penjawat Awam Malaysia (PPAM), Rumah Wilayah Persekutuan (RUMAWIP) and Projek Perumahan Rakyat (PPR). This study was to identify which initiative among those three that offers the best housing needs alongside its goal of implementation, adequate and good quality of home with conducive amenities and environment, affordability and sustainability. The survey questionnaire that was developed was validated and provided to the general public to gain insight and feedback on the effectiveness of the PPAM, RUMAWIP and PPR initiatives. Therefore, the results were summarized according to the public's satisfaction that may be useful in the housing industry and the government for continuous and improvements to ensure continuity in future studies. Results showed that the favourite housing initiative is PPR however many improvements still need to be improved such as pricing, size, facilities and maintenance. Overall, this study is in line with the targeted Sustainable Development Goal (SDGs) 3 of Good Health and Wellbeing as well as Goal 11 of Sustainable Cities and Communities and others which will benefit all.
25
Lopes Junior, Antonio de Moraes, Cristiane Gattini Sbampato, Alexandre Tourino Mendonça, and João Carlos Nordi. "Percepção ambiental e nível de engajamento de produtores rurais no projeto produtor de águas de Mariana (MG)." Revista Brasileira de Educação Ambiental (RevBEA) 19, no. 8 (October 1, 2024): 254–81. http://dx.doi.org/10.34024/revbea.2024.v19.16323.
Full textAbstract:
Objetivou-se com este trabalho avaliar a percepção ambiental dos produtores rurais nos distritos de Furquim e Águas Claras, em Mariana (MG), no processo de adesão e na execução das atividades do Projeto Produtor de Águas de Mariana (PPAM) e construir, a partir da escuta dos diversos discursos dos produtores rurais, meios de aproximação a fim de propiciar o máximo de engajamento na execução de projetos de conservação e recuperação de mananciais. Os resultados demonstraram que a maioria dos produtores que aderiu ao projeto já adotava práticas de conservação e optou em participar pela consciência ambiental que já tinham.
26
Krozer, Steven, Karen L. Johnston, Dean Najarian, Steven Wang, Sherry Fua, Jennifer Kern Sliwa, and Oliver Lopena. "Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation." Perspectives in Psychiatric Care 2023 (December 19, 2023): 1–9. http://dx.doi.org/10.1155/2023/3237737.
Full textAbstract:
Purpose. This post hoc analysis assessed the importance of proper paliperidone palmitate (PP) dose preparation prior to administration and evaluated injection site reactions after dorsogluteal injection of PP once-every-6-months (PP6M) and once-every-3-months (PP3M) formulations from a double-blind (DB) noninferiority study. Design and Methods. Clinically stable patients receiving moderate/high doses of PP once-monthly (PP1M) (156 mg/mL; 234 mg/1.5 mL) or PP3M (546 mg/1.75 mL; 819 mg/2.63 mL) were randomly assigned 2:1 to corresponding dorsogluteal injections of PP6M (1092 mg/3.5 mL; 1560 mg/5 mL) or PP3M (546 mg/1.75 mL; 819 mg/2.63 mL) during a 12-month DB phase. Patients receiving PP6M injections received alternating matching placebo injections every 3 months between active doses to maintain blinding. Prior to administration, each PP formulation was prepared per specific instructions to ensure complete resuspension of the medication. Findings. Of 895 PP6M injections, one of two incomplete injections was possibly related to insufficient shaking before administration; neither resulted in an adverse reaction. After dorsogluteal administration, 59 of 478 patients who received PP6M (12.3%) and 11 of 224 patients who received PP3M (4.9%) reported an injection site–related treatment-emergent adverse event (TEAE), with pain being the most commonly reported (7.7% and 4.0%, respectively). Patient-reported pain decreased from baseline to end point in both groups. During the DB phase, injection site-related TEAEs associated with PP6M injections up to 5 mL and PP3M injections up to 2.63 mL were mild to moderate in severity; none were reported as serious, resulted in treatment discontinuation, or required dermatological consultation. Practice Implications. These results inform provider and patient expectations of PP6M administration and reinforce the importance of proper PP dose preparation and administration; future work could assess safety data from real-world clinical practice. This trial is registered with NCT03345342.
27
Romero Guillena, S. L., H. Marín Mateos, and G. Rodriguez Menendez. "Paliperidone palmitate 6-month formulation for the treatment of schizophrenia: a 14-month follow-up study." European Psychiatry 67, S1 (April 2024): S752. http://dx.doi.org/10.1192/j.eurpsy.2024.1565.
Full textAbstract:
IntroductionRelapse prevention is critical because psychopathology and functionality can worsen in patients with schizophrenia because the repeated episodes and we have strong evidence of antipsychotics efficacy for relapse prevention, but nonadherence rates in patients with schizophrenia are very high, even in comparison with other illness.There is extensive clinical trial evidence for the use of paliperidone palmitate 1-month (PP1M) and paliperidone palmitate 3-month (PP3M) formulations for maintaining treatment continuity and preventing relapses and risk of hospitalizations in patients with schizophrenia. (Najarian et al. Int J Neuropsychopharmacol 2022; 25(3) 238-251). Paliperidone palmitate 6-month (PP6M) formulation is a presentation that provides a dosing interval of once every six months.ObjectivesThe principal aim of this study was to evaluate the effectiveness, safety, and tolerability of the PP6M in patients with non-acute schizophrenia on an outpatient basisMethodsMethods: Sample: 22 patients diagnosed with schizophrenia (DSM 5 criteria) that started treatment with PP6M after being stabilized with PP1M (N:10) or PP3M (N:12) (the treatment dose was not changed in the four months before study inclusion)Bimonthly, the following evaluations were performed during a follow-up period of 14 months:The Clinical Global Impression-Schizophrenia scale (CGI-SCH)Treatment adherence, concomitant medication, adverse events and the number of hospitalizations and emergency visitsEfficacy values: Percentage of patients who remained free of admissions at the end of 14months of follow-up.Other evaluation criteria: Percentage of patients who never visited the emergency department at the end of 14 months of follow-up, average change from baseline visit to the final evaluation as assessed by score obtained on the following scale: GSI-SCH, treatment adherence rate and tolerability.ResultsThe percentage of patients who remained free of admission at the end of the 14 months follow-up was 90% in the total sample, 83% in the PP3M pre-treatment group and 100% in the PP1M pre-treatment group.The percentage of patients who never visited the emergency department at the end of 14 months follow-up was: 81% in the total sample, 75% in the PP3M pre-treatment group and 90% in the PP1M pre-treatment group.At the end of the study, a mean change of +0.12 (±0.11) on the ICG-SCH-SI scale in the total sample, +0.25 (±0.21) in the PP3M pre-treatment group and 0 in the PP1M pre-treatment group.The treatment persistence rate at the 14 month of follow-up was 100% in the total sample.Treatment was well tolerated, and no safety-related adverse events were collected. There were no tolerability-related withdrawals from treatment.ConclusionsIn our study, we found that long-term treatment with paliperidone palmitate 6-month formulation is effective and well tolerated in clinical practice conditions.Disclosure of InterestNone Declared
28
Wahyuni, Risni Sri, Etin Rohmatin, and Laila Putri Suptiani. "Rancangan Media Edukasi Berbasis Comic Book Aksi Sera “PPAM Kesehatan Reproduksi pada Situasi Krisis Kesehatan Remaja” di Kecamatan Tamansari Kota Tasikmalaya." Journal of Midwifery and Health Research 2, no. 1 (November 6, 2023): 29–38. http://dx.doi.org/10.36743/jmhr.v2i1.554.
Full textAbstract:
Bencana termasuk kejadian dikarenakan dari faktor alam, non-alam dan sosial. Angka kejadian bencana di Indonesia menurut BNPB (2022) terjadi hingga 2.152 kali bencana. Dampak bencana mengakibatkan kesehatan reproduksi terganggu. Paket Pelayanan Awal Minimum (PPAM) adalah aktivitas prioritas kesehatan reproduksi dengan mesti cepat diselenggarakan untuk situasi krisis kesehatan. Adanya media edukasi berbasis comic book “Aksi Sera” ini dapat memberikan pengetahuan dan memenuhi kebutuhan kelompok rentan salah satunya remaja ketika pra bencana, ketika bencana serta paska bencana. Tujuan Penelitian membuat produk media edukasi berbasis comic book Aksi Sera bagi remaja di Kecamatan Tamansari Kota Tasikmalaya Metode penelitian tersebut memakai metode penelitian serta pengembangan maupun research and development (RnD). Teknik pengambilan sampel memakai teknik purposive sampling melalui total 38 orang dengan tergolong menuju tahap uji coba barang kumpulan sedikitnya diperoleh 8 orang serta uji coba lapangan diperoleh 30 orang. Analisis data dipakai termasuk analisis melalui kuantitatif serta kualitatif. Hasil peneletian ini yaitu barang media edukasi dengan dasar comic book “Aksi Sera” yang berisi tentang Paket Pelayanan Awal Minimum (PPAM) Kesehatan Reproduksi Untuk Keadaan Krisis Kesehatan Remaja. Penilaian ahli materi diterima nilai prevalensi 92% termasuk pada golongan paling layak. Penilaian ahli media diterima nilai prevalensi 90% termasuk pada golongan paling layak. Hasil uji coba kelompok sedikit diterima nilai 91% termasuk pada golongan paling layak. Hasil uji coba lapangan diterima prevalensi 90,4% termasuk pada golongan paling layak. Kesimpulan penelitian ini menghasilkan produk media edukasi berbasis comic book “Aksi Sera” bagi remaja di Kecamatan Tamansari Kota Tasikmalaya Tahun 2023 melalui delapan langkah penelitian serta perluasan maupun research and development (RnD) yang sangat layak untuk dipakai media edukasi. Bagi remaja diharapkan dapat menggunakan media edukasi berbasis comic book “Aksi Sera” sebagai pedoman kesehatan reproduksi pada saat menghadapi krisis kesehatan
29
Tyagi, Anshul, and Ranjan Bose. "A New Distance Notion for PPAM Space--Time Trellis Codes for UWB MIMO Communications." IEEE Transactions on Communications 55, no. 7 (July 2007): 1279–82. http://dx.doi.org/10.1109/tcomm.2007.900574.
Full text
30
Donn, Judy. "Use of the TES Belt as an Alternative Means of Suspension with the PPAM Aid." Physiotherapy 77, no. 9 (September 1991): 591–92. http://dx.doi.org/10.1016/s0031-9406(10)60378-1.
Full text
31
Escobedo-Aedo, P., J. Merayo-Cano, L. Mata Iturralde, L. Muñoz Lorenzo, S. Ovejero, and S. Sánchez Alonso. "Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients." European Psychiatry 65, S1 (June 2022): S730—S731. http://dx.doi.org/10.1192/j.eurpsy.2022.1886.
Full textAbstract:
Introduction Paliperidone palmitate 1-month (PP1M) is a Long-acting injectable antipsychotic formulation, approved for the treatment of schizophrenia and schizoaffective disorder. Recently, paliperidone palmitate 3-months (PP3M) formulation was introduced, which maintains stability while offering a longer dosing interval for the maintenance treatment in patients previously treated with PP1M. Despite of this, many patients are treated with PP1M without transition to PP3M. Objectives To identify variables explaining maintenance of PP1M treatment instead of going to PP3M. We hypothesize that more severe patients are delayed in transition to PP3M because of expectation to complete stabilization. Methods A descriptive analysis of 123 patients, diagnosed with psychotic disorders, on treatment with paliperidone palmitate 1 month or 3 months, was performed. Age, sex, type of paliperidone treatment, hospitalizations after the initiaton of treatment, years since diagnosis, polytherapy and toxic habits were some of the variables measured and compared between both groups (PP1M and PP3M). Results Most of patients (63,41%) were on PP3M. Both groups shared characteristics like male sex predominance, schizophrenia as the most common diagnosis, having a recent onset diagnosis, same frequency of polypharmacy and same pattern of drug consumption. There was a slight difference between both groups regarding severity. PP1M and PP3M showed respectively 33% and 16,7% of admissions after initiation. Conclusions No clear pattern determines less transition to PP3M from PP1M. No statistical difference was found except form the difference found in admission after change of treatment (to PP1M or PP3M), which could reflect influence of severity in treatment. Future research is needed in order to better elucidate this association. Disclosure No significant relationships.
32
Rojas, L. Gutiérrez, S. Sánchez Alonso, M. García Dorado, and P. Lopez. "Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice." European Psychiatry 64, S1 (April 2021): S539. http://dx.doi.org/10.1192/j.eurpsy.2021.1438.
Full textAbstract:
IntroductionIt has been shown that long-acting treatments can significantly improve adherence, control symptom, and reduce the risk of relapse compared to oral drugs. However, limited real world evidence is available as to whether there are differences among the various formulations marketed.ObjectivesThis study aims to assess the impact on several prognosis variables of PP1M,PP3M,AOM and OAP drugs.MethodsAll adults (≥18 years) with schizophrenia who were initiated on PP1M, PP3M, AOM, or OAP treatment (chlorpromazine,levomepromazine,fluphenazine,haloperidol,ziprasidone,zuclopenthixol,olanzapine,quetiapine,asenapine,amisulpride, risperidone,aripiprazole,paliperidone) between 2017 and 2018 were identified in IQVIA’s database(1.8M of inhabitants from 4 Spanish areas). The rate of hospitalizations, emergency room visits, and treatment persistence was calculated using the Kaplan-Meier method. Survival curves were compared using the log-rank test (Sidak-adjustment),and Cox´s Hazard Ratios (HR) were used for the comparison between groups.ResultsData from 2275 patients were analyzed (PP1M= 387;PP3M=490;AOM=75;OAP=1323).The mean age of patients was 46.8(14.95) years, and 62.9% were male. The hospitalization rate at 12 months was significantly lower (p<0.01) for PP3M (8.3%) than for AOM (21.2%), PP1M (22.1%),and OAP (29.4%).When compared with PP3M use, the HRs were 2.17 for PP1M, 2.22 for AOM,and 2.90 for OAP. Emergency room visits rate at 12 months was also significantly lower (p<0. 01) for PP3M (23%) than for PP1M (36.9%), OAP (43.5%),and AOM (46.2%). Persistence rates were higher for PP3M (91%) than for any other treatment (p<0.01).ConclusionsOur results outline that patients treated with PP3M experienced fewer relapses and decompensations compared to all other treatments analyzed, which might help improve the prognosis and quality of life of patients.Conflict of interestThis study was sponsored by Janssen. M. García and P. López are employees of Janssen.
33
Woodruff, K., C. Chirila, Q. Zheng, K. Van Impe, and I. Nuamah. "Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: An analysis of phase III clinical trial hospital data." European Psychiatry 33, S1 (March 2016): s265—s266. http://dx.doi.org/10.1016/j.eurpsy.2016.01.689.
Full textAbstract:
IntroductionPSY-3011 was a randomized, multicenter, double-blind, non-inferiority study of paliperidone palmitate 3-month injection (PP3M) vs. paliperidone palmitate 1-month injection (PP1M). Adults with schizophrenia were stabilized on PP1M in an open-label (OL) 17-week transition phase. Qualifying subjects at the end of the OL phase were then randomized to PP3M or PP1M in the 48-week double-blind (DB) phase. Healthcare resource utilization (HCRU) between PP3M and PP1M was compared using the HCRU questionnaire during the double-blind (DB) phase.MethodsHCRU was measured at the start of the OL and DB phases, and every 12 weeks during DB until end of study/early withdrawal. Information included hospitalizations, ER visits, day or night clinic stays, outpatient treatment, daily living conditions, and occupational status. Logistic regressions modeled the probability of hospitalization vs. no hospitalization for psychiatric and social reasons, as well as hospitalizations for psychiatric reasons only, during the DB phase. The models controlled for OL baseline hospitalizations, OL phase hospitalizations, and time in study.ResultsThe analysis set included 483 subjects randomized to PP3M and 512 subjects to PP1M during the DB phase. The odds of hospitalization for psychiatric/social reasons during 1 year for PP1M subjects were 1.16 times the odds of hospitalization for PP3M subjects (95% CI: 0.70, 1.93, P = 0.56). For psychiatric reasons only, the odds of hospitalization during 1 year for PP1 M subjects were 1.63 times the odds of hospitalization for PP3M subjects (95% CI: 0.88, 3.02, P = 0.12).ConclusionsPP3M and PP1M demonstrated similar trends in hospitalizations throughout the course of the study.Disclosure of interestThe authors have not supplied their declaration of competing interest.
34
Gillespie, Lynn J., Robert J. Soreng, Roger D. Bull, Peter J. Lange, and Rob D. Smissen. "Morphological and phylogenetic evidence for subtribe Cinninae and two new subtribes, Hookerochloinae and Dupontiinae (Poaceae tribe Poeae PPAM clade)." TAXON 71, no. 1 (January 12, 2022): 52–84. http://dx.doi.org/10.1002/tax.12654.
Full text
35
Hebenton, J., J. Colvin, C. Seenan, and H. Scott. "Early PPAM aid use post-unilateral transtibial amputation is associated with reduced time to prosthetic fitting and finishing rehabilitation." Physiotherapy 102 (November 2016): e147-e148. http://dx.doi.org/10.1016/j.physio.2016.10.170.
Full text
36
Scott, H., J. Hebenton, C. Seenan, and J. Colvin. "Early PPAM aid use post unilateral transtibial amputation is associated with reduced time to prosthetic fitting and finishing rehabilitation." Physiotherapy 103 (December 2017): e125. http://dx.doi.org/10.1016/j.physio.2017.11.110.
Full text
37
Fernández-Miranda, Juan J., Silvia Díaz-Fernández, Domenico De Berardis, and Francisco López-Muñoz. "Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia." Journal of Clinical Medicine 10, no. 7 (April 1, 2021): 1408. http://dx.doi.org/10.3390/jcm10071408.
Full textAbstract:
Paliperidone palmitate every three months (PP3M) is expected to facilitate patient’s treatment compliance and satisfaction. The objective here was to compare PP3M treatment compliance and satisfaction, effectiveness and tolerability, with paliperidone palmitate-monthly (PP1M) in patients with severe schizophrenia. A 24-month prospective, open-label study of patients with severe schizophrenia treated with PP3M after at least 2 years of stabilization with PP1M (n = 84) was carried out. Treatment satisfaction was assessed with the Treatment Satisfaction Questionnaire for Medication (TSQM) and with a Visual Analogue Scale (VAS). Effectiveness was measured with psychiatric hospital admissions and the Clinical Global Impression-Severity (CGI-S) scale. Tolerability assessments included laboratory tests, weight and adverse effects. Reasons for treatment discontinuation were recorded. CGI-S significantly improved after 24 months. Three patients changed back to PP1M due to adverse effects, and four were hospitalized. There were neither abandoning nor significant changes in weight or biological parameters, and lower incidence of side effects, with PP3M treatment. TSQM and VAS scales increased. No differences were found related to doses. Apart from somewhat improvement in treatment adherence, effectiveness, and tolerability, patients with severe schizophrenia lengthy treated with PP1M showed more satisfaction with PP3M, even those who needed high doses to get clinical stabilization.
38
Wallman, Phoebe, Ivana Clark, and David Taylor. "Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice." Journal of Psychopharmacology 35, no. 9 (April 28, 2021): 1091–98. http://dx.doi.org/10.1177/02698811211009794.
Full textAbstract:
Background: The use of antipsychotic long-acting injections (LAI) aims to reduce risk of relapse and hospitalisation in patients with schizophrenia compared with oral medication. Paliperidone palmitate is currently the only LAI that can be administered at three-monthly intervals for maintenance treatment of schizophrenia. Aim: This prospective study aimed to evaluate relapse and continuation in licensed use of paliperidone palmitate three-monthly (PP3M) over a 2-year follow-up in clinical practice. Method: Non-interventional, observational study of patients treated in the South London and The Maudsley NHS Foundation Trust. Results: A total of 166 patients initiated on PP3M, 55 were excluded from the study (non-F20 diagnosis ( n = 43); F20 >65 years old ( n = 12)). Of the 111 patients included, 67 (60%) continued PP3M for 2 years. Overall 102 patients received more than one dose of PP3M and 92 (90%) remained on the same dose of PP3M for the whole of their treatment duration. Relapse (defined as a step-up in clinical care) occurred in eight patients (7%) while on PP3M. The most common reason for discontinuation was patient refusal and the most frequent medication prescribed after discontinuation was paliperidone palmitate one-monthly (PP1M). Post hoc, we analysed outcome in those continuing any form of PPLAI (those continuing with PP3M and those switching back to PP1M). Continuation over 2 years with any PPLAI formulation was 73% (81/111) and relapse was recorded in 9% (10/111). Conclusion: Overall, PP3M was an effective maintenance treatment for schizophrenia after stabilisation on PP1M in a clinical setting.
39
Vanzetto, S., G. Cirnigliaro, V. Battini, E. Piccoli, M. Vismara, C. Viganò, and B. Dell’Osso. "Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study." European Psychiatry 65, S1 (June 2022): S346. http://dx.doi.org/10.1192/j.eurpsy.2022.879.
Full textAbstract:
Introduction Paliperidone Palmitate 3-month (PP3M) formulation, introduced in Italy since 2017, is an effective and safety therapeutic option for patients with schizophrenia, clinically stable with 1-month formulation (PP1M). Only a few “Real World” studies investigated the clinical relevance of PP3M and the long-term clinical and health resource utilization outcomes. Objectives The aim of this retrospective, mirror image study was to evaluate the efficacy of PP3M in terms of continuity of care and number of hospitalizations. Methods Fifty outpatients treated with Paliperidone Palmitate (PP) were recruited from a Community Mental Health Centre (CMHC) in Milan. Statistical analysis were conducted with SPSS 26. Frequencies of hospitalization 6 months before and after the start of PP3M were compared using the McNemar test, setting the significance to p<0.05. Results This study involved 34 patients (68%) treated with PP1M and 16 (32%) treated with PP3M.The median time interval between PP1M and PP3M was 14 months. After the switch to PP3M, 69% of patients continued to visit the CMHC with an unchanged frequency (50% once/month, 6% more than once/month), while 31% with a decreased frequency (once/3 months). No patient increased the frequency of CMHC visits or started visiting it discontinuously. 44% of subjects had had at least one hospitalization prior to the switch and no hospitalizations after (p=0.016). Moreover, no patients showed increased hospitalizations Conclusions In this study PP3M clinical relevance was confirmed comparing pre-initiation and post-initiation 6-months time intervals: hospitalizations number significantly decreased, while the continuity of care was preserved. Further studies on a greater sample are necessary to support these preliminary data. Disclosure No significant relationships.
40
Corbeil, Olivier, Anne-Marie Essiambre, Raphaëlla Rosebush-Mercier, Gabrielle Rhéaume, Marie-France Demers, Marc-André Roy, and Olivier Corbeil. "M197. SEASONAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: OUTCOMES IN NATURALISTIC SETTINGS (SEASONS STUDY) OBSERVATIONAL RETROSPECTIVE MULTICENTRE CANADIAN STUDY ON 3MONTH-FORMULATION OF LONG-ACTING INJECTABLE PALIPERIDONE PALMITATE." Schizophrenia Bulletin 46, Supplement_1 (April 2020): S211—S212. http://dx.doi.org/10.1093/schbul/sbaa030.509.
Full textAbstract:
Abstract Background The 3 month-formulation of long-acting injectable paliperidone palmitate (PP3M) is available in Canada since 2016. However, there are still limited data on its use in real life setting. Methods This ongoing study retrospectively reviews the use of this formulation in 6 centers across Canada (targeted n=250 patients). Data on PP3M use (dosage, duration of exposure, reasons for initiating PP3M and stopping it, if applicable) are recorded, as well as its clinical impact (hospitalizations, global severity of illness as measured by Clinical Global Impression Scales), the main outcome variable being discontinuation of PP3M. Results Preliminary data are available for the first 35 patients coming from 3 participating centers. 31/35 are men, on average 35 years old, Caucasian (25/35), exposed to antipsychotics for an average of 7 years (sd 2 yrs) with an average 2-year exposure to the 1-month formulation of long-acting injectable paliperidone palmitate (PP1M). 21/35 had also at least one concomitant disorder (some may be combined), such as substance use disorder, personality disorder or anxious disease, and 10/35 were under a court treatment order. Clinical Remission (as defined as a CGI S score equal or less to 3) was maintained in 27/35 subjects over an average of 14 months (sd 9 months) of PP3M. However, 8 patients stopped their treatment dues to compromise stability (2 patients), side effects (2 patients: somnolence, 1 patient: pain discomfort at site of injection) or loss to follow-up (3 patients). Discussion In this Canadian study, preliminary observations in real life settings suggest that PP3M may be an interesting option for patient previously stabilized on PP1M, although the number of treatment cessations might suggest that the clinical effectiveness of PP3M vs. PP1M may not be similar in all subjects.
41
Ispir, S. N., E. Yıldız, H. R. Demirel, H. Söylemez, and M. Aydın. "Retrospective Assessment of Metabolic Syndrome and Cardiovascular Disease Risk Following Monthly and Three-Month Long-Acting Paliperidone Palmitate Treatment in Schizophrenia." European Psychiatry 67, S1 (April 2024): S214—S215. http://dx.doi.org/10.1192/j.eurpsy.2024.460.
Full textAbstract:
IntroductionPatients with schizophrenia exhibit a higher prevalence of metabolic syndrome and cardiovascular diseases compared to the general population, resulting in increased mortality rates. The extent of this risk may vary based on the specific treatment employed.ObjectivesThis study aims to compare the risk assessments of metabolic syndrome and cardiovascular diseases in schizophrenia patients who transitioned from monthly long-acting paliperidone palmitate (PP1M) treatment to three-month long-acting paliperidone palmitate (PP3M) treatment during both treatment periods.MethodsThe research was conducted at the Psychiatry Clinic and Psychotic Disorders Outpatient Clinic of Selcuk University Faculty of Medicine. Eligible participants included patients under PP3M treatment for a minimum of 6 months and undergoing continuous monitoring in the psychotic disorders outpatient clinic. Sociodemographic and clinical data, scales, laboratory values, and measurements taken both before and during the use of PP3M and PP1M were retrieved from file records, encompassing assessments, analyses, and examinations conducted in accordance with the “Psychotic Disorders - Treatment Monitoring Protocol.” Ethical approval was obtained from the Selcuk University Ethics Committee.Results Among the 31 patients transitioning from PP1M to PP3M treatment, 15 (48.4%) were female. The mean age of the patients was 44.4±14.4 years. No statistically significant differences were observed in the mean values of clinical evaluation and side effect assessment scales, body mass index (BMI), waist-to-hip ratio, systolic blood pressure, glucose levels, cholesterol levels, prolactin levels, and thyroid-stimulating hormone (TSH) measurements between the pre- and post-treatment phases (p>0.05). However, a significant difference was identified in the mean Qrisk3 values, a cardiovascular risk index, in two distinct measurements (10-year risk score: PP1M 3.7±4.2 and PP3M 4.6±4.8, p=0.003).Conclusions Our study, designed to investigate the impact of the monthly and three-month long-acting formulations of the same antipsychotic drug on patients’ clinical status, side effects, and general health parameters, found that PP3M treatment did not significantly differ from PP1M treatment in terms of Qrisk3 values. Despite the lack of statistical significance between the parameters used in Qrisk3 calculation, the observed significant difference in Qrisk3 values is attributed to variations in age. In order to promote the widespread adoption of long-acting treatments in schizophrenia management, clinicians should engage in comprehensive comparative studies assessing both efficacy and side effects.Disclosure of InterestNone Declared
42
Alphs, Larry, Ibrahim Turkoz, Virginia Smith-Swintosky, Alexander Keenan, Emily Abraham, Alain Schotte, Eileen Hooker, et al. "Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system." BMJ Open 13, no. 4 (April 2023): e064675. http://dx.doi.org/10.1136/bmjopen-2022-064675.
Full textAbstract:
ObjectiveTo evaluate the feasibility of conducting a large clinical trial within the Rwandan mental healthcare system that would establish the safety, efficacy and benefit of paliperidone palmitate once-monthly (PP1M) and once-every-3-months (PP3M) long-acting injectable formulations in adults with schizophrenia.Study designAn open-label, prospective feasibility study.Setting/Participants33 adult patients with schizophrenia were enrolled at 3 sites across Rwanda.InterventionsThe study design included 3 phases of treatment: an oral run-in to establish tolerability to risperidone (1 week), lead-in treatment with flexibly dosed PP1M to identify a stable dose (17 weeks) and maintenance treatment with PP3M (24 weeks).Primary and secondary outcome measuresFeasibility endpoints included compliance with governmental and institutional requirements, acceptable supply chain delivery and proper onsite administration of risperidone/PP1M/PP3M, adequate site infrastructure, adequate training of clinical staff and successful completion of study procedures and scales. A variety of study scales were administered to assess outcomes relevant to patients, caregivers, clinicians and payers in Rwanda and other resource-limited settings.ResultsThis study was terminated early by the sponsor because certain aspects of study conduct needed to be addressed to maintain Good Clinical Practice requirements and meet regulatory standards. Results identified areas for improvement in study execution, including study governance, site infrastructure, study preparation and conduct of procedures, study budget and study assessments. Despite the identification of areas in need of adjustment, none of these limitations were considered insurmountable.ConclusionsThis work was designed to strengthen global research in schizophrenia by building the capacity of researchers to prepare and conduct pharmaceutical trials in resource-limited settings. Although the study was ended early, modifications motivated by the results will facilitate the successful design and completion of more comprehensive studies, including an ongoing, follow-up interventional trial of PP1M/PP3M in a larger population of patients in Rwanda.Trial registration numberNCT03713658
43
Volz, H. P. "Paliperidonpalmitat in der Langzeittherapie der Schizophrenie." Die Psychiatrie 14, no. 02 (April 2017): 116–23. http://dx.doi.org/10.1055/s-0038-1669565.
Full textAbstract:
ZusammenfassungPaliperidon, ein aktiver Metabolit von Risperidon, der nahezu nicht weiter metabolisiert wird, ist ein Antipsychotikum der zweiten Generation, das vorwiegend als Dopamin-D2– und Serotonin-5HT2A-Blocker wirkt. Dieses Molekül steht zur oralen Anwendung seit vielen Jahren zur Verfügung. Zudem gibt es eine Depot-Formulierung (Paliperidonpalmitat), die in einmonatigem Abstand gluteal oder deltoidal injiziert wird (PP1M). Durch die Fortenwicklung steht nun sein einiger Zeit eine Depot-Formulierung zur Verfügung, bei der ein Drei-Monats-Injektionsintervall ausreichend ist (PP3M). In der vorliegenden Arbeit werden die Eigenschaften dieses Depots beschrieben und es wird auf die beiden zentralen Wirksamkeitsstudien eingegangen. Praktische Hinweise zur Eindosierung, zum Wechsel von PP1M auf PP3M und zur Langzeitbehandlung ergänzen die Arbeit.
44
Chinen, *Madoka, Yosuke Saga, Hiroshi Horio, Chih-Lin Chiang, and Akihide Wakamatsu. "TREATMENT PERSISTENCE OF PALIPERIDONE PALMITATE 3-MONTH IN PATIENTS WITH SCHIZOPHRENIA -AN ANALYSIS OF JAPAN MEDICAL DATA CENTER CLAIMS DATABASE." International Journal of Neuropsychopharmacology 28, Supplement_1 (February 2025): i163. https://doi.org/10.1093/ijnp/pyae059.281.
Full textAbstract:
Abstract Background Paliperidone palmitate three-month (PP3M) is a long-acting injectable antipsychotic approved in Japan since November 2020. It is indicated for patients with schizophrenia who have been stabilized through at least 4 months of PP1M monotherapy without concomitant use of oral antipsychotics. Furthermore, the approved label discourages the continuation of PP3M treatment after the initiation of concomitant antipsychotic use. The approved patient population of PP3M in Japan is more limited compared to other counties, and there is a paucity of real-world data on patients who have received PP3M as monotherapy. Aims & Objectives The study aims to describe the clinical characteristics of patients receiving PP3M treatment, and to examine the treatment persistence of PP3M monotherapy in the real-world setting in Japan. Methods We conducted a retrospective cohort study using the Japan Medical Data Center (JMDC) claims database. This database covers private sector employees and their dependents, and includes data only for individuals under 75 years old of age [1]. We extracted data from the database to identify patients with schizophrenia (ICD10 code F20) who initiated PP3M treatment between November 2020 and June 2022. The current analysis included patients who had transitioned from PP1M monotherapy to PP3M monotherapy in accordance with the approved label of PP3M in Japan. The treatment persistence of PP3M monotherapy was assessed using the Kaplan-Meier survival function. This analysis considered both the discontinuation of PP3M and the initiation of concomitant use of oral antipsychotics as events. The end of available data and study period were considered as censoring. Results As of June 2022, a total 62 patients in the database met the patient selection criteria. The mean age (SD) at the initiation of PP3M was 40.1 (9.1) years old, 29 patients (46.8%) were male. Approximately half of the patients (48.4%) were employed at the baseline. The treatment persistence of PP3M monotherapy was found to be 88.8% at 6 months and 75.7% at 12 months. Notably, employed patients had a higher 12-month treatment persistence rate (85.7%) in PP3M monotherapy compared with unemployed patients (66.2%). Additionally, the treatment persistence of PP3M was found to be 98.2% at 6 months and 90.1% at 12 months if the concomitant use of oral antipsychotic during PP3M treatment is not considered an event. This study will further incorporate updated results based on the March 2023 cut-off data. Discussion & Conclusion In this study, we will present evidence demonstrating the high treatment persistence of PP3M in Japan’ s clinical practice setting. Additionally, we will update the analysis to include the dataset as of March 2023 to ensure the presentation of the latest findings. Furthermore, we will provide additional data from patients who transitioned from PP1M to PP3M, irrespective of whether they were using concomitant use of antipsychotics at the time of transition. These results will contribute to a more comprehensive understanding of treatment persistence of PP3M in the real-world setting. References 1.Nagai, K. et al. (2020) 'Data resource profile: JMDC claims databases sourced from Medical Institutions,' Journal of General and Family Medicine, 21(6), pp. 211–218.
45
Benito, A., and A. Sanchez-Cabezudo. "Efficacy and tolerability of half-yearly long acting injectable palmitate paliperidone after 12 months follow-up." European Psychiatry 67, S1 (April 2024): S724. http://dx.doi.org/10.1192/j.eurpsy.2024.1504.
Full textAbstract:
IntroductionThis retrospective study analysed the clinical efficacy, tolerability and treatment satisfaction of patients who switched from receiving palmitate paliperidone monthly (PP1M) to palmitate paliperidone six-monthly (PP6M) after 12 months of follow-up. A total of 48 patients (31 men and 17 women) with recently diagnosed schizophrenia were included.ObjectivesTo assess the clinical efficacy, tolerability and treatment satisfaction in a sample of recently diagnosed schizophrenic patients who switched from receiving palmitate paliperidone monthly (PP1M) to palmitate paliperidone six-monthly (PP6M)MethodsThe sample included a total of 48 recently diagnosed schizophrenic (1-5 years) from three Mental Health units in the province of Toledo (Spain). The inclusion criteria were a diagnosis of schizophrenia (based on the ICD-10 criteria), the start of treatment with Long Acting Injectable Paliperidone Palmitate six-monthly (previously with palmitate paliperidone monthly), and the non-utilization of another neuroleptic treatment. A series of demographic variables were recorded, PANSS scale was used to to identify the presence and severity of psychopathology symptoms and the CGI scale was used to assessed the severity of the symptoms finally time to relapse was measured (primary outcome). The scales were again applied at baseline, 3 and 6 and 12 months after the start of treatmentResultsN=48 patients (31 males and 17 females), with a mean age of 31 years. 4.3 years of evolution of illness. During the follow-up period only 2 patients (4%) relapsed. Results showed an improvement in PANSS (baseline 50.8, 3 months 41.9, 6 months 37.3, 12 months 26.1), likewise and improvement in CGI was observed (baseline 4.1, 3 months 3.4, 6 months 2.9, 12 months 2.5).In terms of tolerability, no secundary effects were reported after treatment change, suggesting a good safety profile and predictable tolerability of PP6M. Patient satisfaction with treatment also improved over time. The study reports that 87% of patients accepted the switch from PP1M to PP6M, with reasons for switching including reduced frequency of administration and increased comfort. Most patients (95%) received antipsychotic monotherapy.ConclusionsIn conclusion, this study suggests that switching from PP1M to PP6M in patients with recently diagnosed schizophrenia was associated with maintained clinical stability, good tolerability and improved patient satisfaction with treatment. These findings support the efficacy and clinical utility of PP6M as a convenient and effective treatment option for patients with schizophrenia.Disclosure of InterestNone Declared
46
de Filippis, Renato, Filippo Antonio Staltari, Matteo Aloi, Elvira Anna Carbone, Marianna Rania, Laura Destefano, Luca Steardo Jr., Cristina Segura-Garcia, and Pasquale De Fazio. "Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study." Brain Sciences 13, no. 4 (March 29, 2023): 577. http://dx.doi.org/10.3390/brainsci13040577.
Full textAbstract:
We hypothesized that shifting from oral second-generation antipsychotics (SGA) to their long-acting injectable (LAI) counterpart would be beneficial for the psychopathological, cognitive, social, and general health domains in outpatients suffering from schizophrenia. We aimed to evaluate the prospective usefulness of SGA-LAI treatment by carrying out a head-to-head comparison of two different medications (i.e., aripiprazole monohydrate (Ari-LAI) and paliperidone palmitate 1 and 3 month (PP1M, PP3M)) in a real-world setting, assessing the effectiveness and tolerability of Ari-LAI and PP1M/PP3M over a 15 month follow-up. A total of 69 consecutive individuals affected by schizophrenia were screened for eligibility. Finally, 46 outpatients (29 treated with Ari-LAI, 13 with PP1M, and four with PP3M) were evaluated through clinical, functional, and neuropsychological assessment administrated at baseline and after 3-, 12-, and 15-month follow-up periods. Moreover, periodic general medical evaluations were carried out. We estimated an overall improvement over time on the explored outcomes, without differences with respect to the type of LAI investigated, and with a global 16.4% dropout rate. Our findings suggest that switching from oral SGA to SGA-LAIs represents a valid and effective treatment strategy, with significant improvements on psychopathological, cognitive, social, and clinical variables for patients suffering from schizophrenia, regardless of the type of molecule chosen.
47
Yasuhara-Bell, Jarred, Ryo Kubota, Daniel M. Jenkins, and Anne M. Alvarez. "Loop-Mediated Amplification of the Clavibacter michiganensis subsp. michiganensis micA Gene Is Highly Specific." Phytopathology® 103, no. 12 (December 2013): 1220–26. http://dx.doi.org/10.1094/phyto-03-13-0078-r.
Full textAbstract:
Loop-mediated amplification (LAMP) was used to specifically identify Clavibacter michiganensis subsp. michiganensis, causal agent of bacterial canker of tomato. LAMP primers were developed to detect micA, a chromosomally stable gene that encodes a type II lantibiotic, michiganin A, which inhibits growth of other C. michiganensis subspecies. In all, 409 bacterial strains (351 C. michiganensis subsp. michiganensis and 58 non-C. michiganensis subsp. michiganensis) from a worldwide collection were tested with LAMP to determine its specificity. LAMP results were compared with genetic profiles established using polymerase chain reaction (PCR) amplification of seven genes (dnaA, ppaJ, pat-1, chpC, tomA, ppaA, and ppaC). C. michiganensis subsp. michiganensis strains produced eight distinct profiles. The LAMP reaction identified all C. michiganensis subsp. michiganensis strains and discriminated them from other C. michiganensis subspecies and non-Clavibacter bacteria. LAMP has advantages over immunodiagnostic and other molecular detection methods because of its specificity and isothermal nature, which allows for easy field application. The LAMP reaction is also not affected by as many inhibitors as PCR. This diagnostic tool has potential to provide an easy, one-step test for rapid identification of C. michiganensis subsp. michiganensis.
48
Garcia-Portilla, Maria Paz, Pierre-Michel Llorca, Giuseppe Maina, Vasilis P. Bozikas, Halise Devrimci-Ozguven, Sung-Wan Kim, Paul Bergmans, Irina Usankova, and Katalin Pungor. "Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia." Therapeutic Advances in Psychopharmacology 10 (January 2020): 204512532092634. http://dx.doi.org/10.1177/2045125320926347.
Full textAbstract:
Background: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance treatment of adult patients with schizophrenia. This single-arm, open-label, phase IIIb study evaluated the efficacy and safety of converting patients with schizophrenia stabilized with paliperidone palmitate 1-month (PP1M) to PP3M in a naturalistic clinical setting. Methods: After screening (days –7 to 1), patients were converted from PP1M (50–150 mg eq.) to PP3M (175–525 mg eq.), and entered a 52-week, flexible-dose PP3M treatment period. The primary efficacy endpoint was symptomatic remission (SR) (Andreasen criteria) at last observation carried forward (LOCF) endpoint. Results: Patients ( n = 305) received PP3M, of whom 291 (95.4%) completed the study. Doses of PP3M remained stable during the 12-month treatment period, and changes in dose were uncommon. Overall, 56.8% of patients [95% confidence interval (CI): 51.0, 62.4] achieved SR, and 31.8% achieved both symptomatic and functional remission (Personal and Social Performance scale total score > 70) at LOCF endpoint. Secondary endpoint results were generally consistent with primary endpoint results. There were improvements in Positive and Negative Syndrome Scale total, subscale and Marder factor scores, and also Clinical Global Impression-Severity and -Change scores from baseline to LOCF endpoint. Carer burden was reduced, and the proportion of patients requiring hospitalization for psychiatric reasons decreased from 13.5% in the 12 months prior to baseline to 4.6% during the treatment period. No new safety signals were identified. Conclusion: Results from this naturalistic study were similar to those observed in previous randomized clinical trials of PP3M and underline the importance of continuous maintenance treatment in patients with schizophrenia.
49
Cai, Hua, Yan-Ling Xiao, Ying Guo, and Jian-Gang Li. "Controllable assembly of a three-dimensional metal–organic supramolecular framework displaying hydrogen-bonding and π–π stacking interactions." Acta Crystallographica Section C Structural Chemistry 70, no. 7 (June 25, 2014): 722–25. http://dx.doi.org/10.1107/s2053229614014247.
Full textAbstract:
The complex poly[[aqua(μ2-phthalato-κ2O1:O2){μ3-2-[3-(pyridin-2-yl)-1H-pyrazol-1-yl]acetato-κ4N2,N3:O:O′}{μ2-2-[3-(pyridin-2-yl)-1H-pyrazol-1-yl]acetato-κ3N2,N3:O}dizinc(II)] dihydrate], {[Zn2(C10H8N3O2)2(C8H4O4)(H2O)]·2H2O}n, has been prepared by solvothermal reaction of 2-[3-(pyridin-2-yl)-1H-pyrazol-1-yl]acetonitrile (PPAN) with zinc(II). Under hydrothermal conditions, PPAN is hydrolyzed to 2-[3-(pyridin-2-yl)-1H-pyrazol-1-yl]acetate (PPAA−). The structure determination reveals that the complex is a one-dimensional double chain containing cationic [Zn4(PPAA)4]4+structural units, which are further extended by bridging phthalate ligands. The one-dimensional chains are extended into a three-dimensional supramolecular architectureviahydrogen-bonding and π–π stacking interactions.
50
Deleforge, Antoine, Florence Forbes, and Radu Horaud. "Acoustic Space Learning for Sound-Source Separation and Localization on Binaural Manifolds." International Journal of Neural Systems 25, no. 01 (January 6, 2015): 1440003. http://dx.doi.org/10.1142/s0129065714400036.
Full textAbstract:
In this paper, we address the problems of modeling the acoustic space generated by a full-spectrum sound source and using the learned model for the localization and separation of multiple sources that simultaneously emit sparse-spectrum sounds. We lay theoretical and methodological grounds in order to introduce the binaural manifold paradigm. We perform an in-depth study of the latent low-dimensional structure of the high-dimensional interaural spectral data, based on a corpus recorded with a human-like audiomotor robot head. A nonlinear dimensionality reduction technique is used to show that these data lie on a two-dimensional (2D) smooth manifold parameterized by the motor states of the listener, or equivalently, the sound-source directions. We propose a probabilistic piecewise affine mapping model (PPAM) specifically designed to deal with high-dimensional data exhibiting an intrinsic piecewise linear structure. We derive a closed-form expectation-maximization (EM) procedure for estimating the model parameters, followed by Bayes inversion for obtaining the full posterior density function of a sound-source direction. We extend this solution to deal with missing data and redundancy in real-world spectrograms, and hence for 2D localization of natural sound sources such as speech. We further generalize the model to the challenging case of multiple sound sources and we propose a variational EM framework. The associated algorithm, referred to as variational EM for source separation and localization (VESSL) yields a Bayesian estimation of the 2D locations and time-frequency masks of all the sources. Comparisons of the proposed approach with several existing methods reveal that the combination of acoustic-space learning with Bayesian inference enables our method to outperform state-of-the-art methods.